Showing 4311-4320 of 5303 results for "".
- Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapyhttps://practicaldermatology.com/news/fibrocell-to-collaborate-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-rdeb-gene-therapy/2460004/Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disord
- L'Oreal To Support Reconstruction of Notre Dame Cathedralhttps://practicaldermatology.com/news/loreal-to-support-reconstruction-of-notre-dame-cathedral/2460003/The Bettencourt Meyers family and the L’Oréal Group are making a joint donation of 100 million euros toward the “renaissance” of the Notre-Dame Cathedral, which they describe as a symbol of French heritage and common history.
- La Roche-Posay to Sponsor a Patient to Visit Thermal Dermatology Center: Accepting Nominationshttps://practicaldermatology.com/news/la-roche-posay-to-sponsor-a-patient-to-visit-thermal-dermatology-center-accepting-nominations/2459995/La Roche-Posay brand is sponsoring a patient to travel to the Thermal Dermatology center in the town of La Roche-Posay, France this fall. With 8,000 visitors per year, a third of whom are children, the La Roche-Posay thermal center is Europe’s leading thermal dermatology center for sensitiv
- Biofrontera Acquires Cutanea Life Scienceshttps://practicaldermatology.com/news/biofrontera-acquires-cutanea-life-sciences/2459959/Biofrontera Inc., USA entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan as the seller. Maruho holds approximately 20 percent of Biofrontera AG. Cutanea is a US-based phar
- Cutera Hosts Beauty Talk with Sadick and Sadickhttps://practicaldermatology.com/news/cuter-hosts-beauty-talk-with-sadick-and-sadick/2459960/Dermatologist Neil Sadick, MD and his daughter Sydney Sadick, an in-the-know fashion journalist, talked about everything from state-of-the-art skin brightening treatments to the newest injectables and how to get svelte without sweating or surgery at
- Are Skin Diseases More Common Than Previously Held?https://practicaldermatology.com/news/are-skin-diseases-more-common-than-previously-held/2459964/Skin diseases may be more common than previously believed, according to a new study in the Journal of the European Academy of Dermatology and Venereology that estimates the prevalence of skin diseases outside of the
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of D
- Constellation Alpha Capital Corp. Signs Letter of Intent to Acquire DermTech, Inc.https://practicaldermatology.com/news/constellation-alpha-capital-corp-signs-letter-of-intent-to-acquire-dermtech-inc/2459970/Constellation Alpha Capital Corp., a special purpose acquisition company, has executed a non-binding Letter of Intent to merge with DermTech, Inc., a molecular genomics company with an initial focus on skin cancer. DermTech markets and develops products that facilitate the early detection of skin
- History of Dermatology Society Names Samuel J. Zakon Awardeehttps://practicaldermatology.com/news/history-of-dermatology-society-names-samuel-j-zakon-awardee/2459972/Frederick C. Gaede, BA, MAS, has received the Samuel J. Zakon Award in the History of Dermatology for his article entitled “Henry Granger Piffard, MD and His Photogenic Pistol Cartridges.” The Award was announced at the forty-sixth annual meeting of the History of Dermatology Society
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription